Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Methylconalamin Injection in Healthy Subjects
NCT07158099Phase 1Completed
- Sponsor
- Wanbangde Pharmaceutical Holding Group
- Start
- Sep 2025
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Methylconalamin for Injection in vitamin B12 deficiency (2 arms), sponsored by Wanbangde Pharmaceutical Holding Group. Primary endpoints: Peak Plasma Concentration, Area under the plasma concentration versus time curve from time zero to time t and 1 more. Started Sep 2025; status: completed.
02
Drugs
Methylconalamin for Injection
03
Conditions
vitamin B12 deficiency
Beyond the preview
Go deeper on NCT07158099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158099.